Agios is a biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases, with an active research pipeline across both therapeutic areas. Its goal is to develop programmes that target the specific changes in cellular metabolism that cause cancer and rare genetic metabolic disorders. Its drug candidates are being designed to reverse those changes. All Agios programmes focus on genetically identified patient populations leveraging its knowledge of metabolism, biology and genomics.